Biostate AI and Weill Cornell Medicine Develop AI for Leukemia Care

Biostate AI and Weill Cornell Medicine have announced a strategic collaboration to develop artificial intelligence models aimed at personalizing leukemia care, as stated in a press release. The partnership will initially focus on acute myeloid leukemia (AML), utilizing Weill Cornell's extensive biorepository of bone marrow and blood samples.

Biostate AI will employ its proprietary barcode-integrated reverse transcription (BIRT) technology for RNA sequencing to analyze RNA expression from patient samples. This data will be used to pre-train and fine-tune a transformer-based AI model, which will assist in AML subtype stratification, disease prognosis, and therapy selection.

The collaboration will begin with a pilot phase involving 1,000 retrospective samples, with plans to expand to 50,000 samples upon achieving certain technical milestones. This effort aims to enhance the precision of treatment decisions, potentially improving patient outcomes by tailoring therapies such as bone marrow transplants and BCL-2 inhibitors.